3 completed, 3 recruiting, 2 withdrawn. 8 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 3, Recruiting 3, Withdrawn 2 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
Follow CNS Tumor: new trials by email Literature Review of CNS Tumor trials Research Report on CNS Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of PHST001 in Advanced Solid Tumors PHST001, Paclitaxel, Topotecan - Advanced Solid Tumors, Ovarian Cancer | Phase 1 | Recruiting | Pheast Therapeutics | 426 | 2025-03-31 | 2026-10-05 |
| Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors Idasanutlin, Selinexor - Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Withdrawn | St. Jude Children's Research Hospital | 2024-03-01 | 2024-03-27 | |
| A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling avapritinib - Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm | Phase 1 / Phase 2 | Completed | Blueprint Medicines Corporation | 29 | 2022-02-24 | 2026-01-13 |
| Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations Infigratinib - Advanced Solid Tumor, CNS Tumor | Phase 1 / Phase 2 | Withdrawn | Helsinn Healthcare SA | 2021-10-01 | 2023-02-23 | |
| ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS) - Diffuse Midline Glioma (DMG), Glioblastoma | Phase 1 | Recruiting | Sabine Mueller, MD, PhD | 208 | 2021-08-23 | 2026-06-11 |
| INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies Nivolumab and Entinostat - CNS Tumor, Solid Tumor | Phase 1 / Phase 2 | Recruiting | University Hospital Heidelberg | 91 | 2020-05-26 | 2024-02-07 |
| Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors Prexasertib, Cyclophosphamide, Gemcitabine - Brain Tumor, Brain Tumor, Recurrent | Phase 1 | Completed | St. Jude Children's Research Hospital | 21 | 2019-08-08 | 2025-02-07 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Gemcitabine, ribociclib, sonidegib - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 68 | 2018-03-05 | 2024-05-31 |
Central Nervous System Neoplasms (8) · Brain Neoplasms (2) · Ependymoma (2) · Glioblastoma (2) · Glioma (2) · Medulloblastoma (2) · Microphthalmia, Isolated, with Coloboma 5 (2) · Recurrence (2) · Rhabdoid Tumor (2) · Astrocytoma (1) · Breast Neoplasms (1) · Carcinosarcoma (1) · Cholangiocarcinoma (1) · Choroid Plexus Carcinoma (1) · Endometrial Neoplasms (1)
Neoplasms by Site (8) · Nervous System Diseases (8) · Nervous System Neoplasms (8) · Neoplasms (7) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Neoplasms, Complex and Mixed (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Neuroepithelial (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Disease Attributes (2) · Glioma (2)
Gemcitabine (3) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Cyclophosphamide (1) · Doxorubicin (1) · Fluorouracil (1) · Folfox protocol (1) · IFL protocol (1) · Leucovorin (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · ONC206 (1) · Paclitaxel (1) · RG7388 (1) · Radiation (1)
St. Jude Children's Research Hospital (3) · Blueprint Medicines Corporation (1) · Helsinn Healthcare SA (1) · Pheast Therapeutics (1) · Sabine Mueller, MD, PhD (1) · University Hospital Heidelberg (1)
United States (6) · Germany (3) · Australia (2) · Austria (2) · Canada (2) · France (2) · Netherlands (2) · Switzerland (2) · Italy (1) · South Korea (1) · Sweden (1) · United Kingdom (1)
Giles W. Robinson, MD (2) · Amar Gajjar, MD (1) · Olaf Witt (1) · Sabine Mueller, MD, PhD (1)
PMID 32503469, PMID 35157764, PMID 41256696
2018 (1), R01CA266596 (1)